CVRs Popping Up Far From Biotech World

Law360, New York (August 19, 2013, 4:04 PM EDT) -- A European industrial merger Monday is the latest deal to include a contingent value right, the useful but often gnarly dealmaking tool that is enjoying a small surge outside its traditional life sciences and biotech turf.

Sweden's Atlas Copco Group AB will pay $9.25 per share in cash for Edwards Group Ltd., a British maker of industrial vacuum systems, plus a CVR worth up to $1.25 per share if Edwards posts at least $785 million in 2013 revenue and $152 million in adjusted earnings before interest,...
To view the full article, register now.